modelOxyphenbutazone
Extends from Pharmacolibrary.Drugs.ATC.S.S01BC02.
Information
| name: | Oxyphenbutazone | |
| ATC code: | S01BC02 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 10 | L |
| clearance: | 1 | L/h |
| other parameters in model implementation | ||
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) formerly used for its analgesic and anti-inflammatory properties, primarily in the treatment of rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal conditions. It is a metabolite of phenylbutazone. Due to serious adverse effects including bone marrow suppression and agranulocytosis, oxyphenbutazone has been withdrawn or severely restricted in many countries and is not commonly used today.
Pharmacokinetics
Estimated pharmacokinetic parameters for adults assuming typical NSAID PK characteristics. No recent or accessible peer-reviewed publication directly reports detailed PK model for oxyphenbutazone in humans.
References
Chay, S, et al., & Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. Journal of veterinary pharmacology and therapeutics 7(4) 265–276. DOI:10.1111/j.1365-2885.1984.tb00911.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/6512917
Brouwers, JR, & de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical pharmacokinetics 27(6) 462–485. DOI:10.2165/00003088-199427060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7882636
Tobin, T, et al., & Lees, P (1986). Phenylbutazone in the horse: a review. Journal of veterinary pharmacology and therapeutics 9(1) 1–25. DOI:10.1111/j.1365-2885.1986.tb00008.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3517382
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)